Development of aerosolized encapsulated recombinant ACE2 for treating COVID-19 early symptom patients

开发雾化封装重组 ACE2 用于治疗 COVID-19 早期症状患者

• 批准号: 554607-2020
• 负责人: PratapSingh, Anubhav
• 金额: $ 3.64万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=705360
• 关键词: Development; aerosolized; encapsulated; recombinant; ACE2

COVID-19 has generated a global pandemic due to lack of effective vaccine and reliable clinically tested treatments. With more than 5 million people infected globally, the number of deaths surpassed 325 thousand globally, and 6 thousand in Canada by mid-May 2020, and is expected to increase. Most global medical research efforts are currently focused on the creation of a vaccine, expected to be available in at least 12 months. Attention has also been dedicated to the treatment of intensive care unit (ICU) patients with lung tissue damage. However, infected people who are starting to show typical initial symptoms, are being overlooked in both global and Canadian efforts. Large parts of the world are unable to provide adequate testing for the public at large due to a shortage of tests or components thereof. Without adequate and timely treatment, these patients eventually evolve into ICU patients, potentially overwhelming our healthcare system. The possibility of containment of the virus reproduction rate in patients experiencing typical early symptoms is the main inspiration behind this proposal. The team of experts from the University of British Columbia (across Faculties of Land & Food Systems, Science, Applied Science, Mechanical Engineering, and Medicine), the St. Paul's Sinus Centre (Center of Heart and Lung Innovation), BC, and the Woolcock Institute of Medical Research (University of Sydney), Australia, in partnership with equipment manufacturer Enwave Inc., BC, proposes to develop a breathable decoy: inhalable microparticles using encapsulated recombinant Angiotensin-converting enzyme 2 (rhACE2) that binds to the virus-receptors. These microparticles will be designed to be released inside the respiratory tract of early symptoms patients, via inhalers, to bind to the virus surface before the virus reaches the target. Our solution does not aim to be a vaccine for Covid-19, rather aims to exploit the virus-receptor affinity to create a solution to treat the symptoms of SARS-CoV-2 infection.

由于缺乏有效的疫苗和可靠的临床试验治疗方法，COVID-19已造成全球大流行。全球感染人数超过500万，截至2020年5月中旬，全球死亡人数超过32.5万，加拿大死亡人数超过6000，预计还会增加。目前，大多数全球医学研究工作都集中在创造一种疫苗上，预计至少在12个月内可用。还关注了对具有肺组织损伤的重症监护室（ICU）患者的治疗。然而，在全球和加拿大的努力中，开始表现出典型的初始症状的感染者被忽视了。世界上大部分地区由于缺乏测试或测试组件而无法为广大公众提供充分的测试。如果没有充分和及时的治疗，这些患者最终会演变成ICU患者，可能会使我们的医疗保健系统不堪重负。在经历典型早期症状的患者中遏制病毒繁殖率的可能性是这一提议背后的主要灵感。 来自不列颠哥伦比亚省大学（包括土地与食品系统学院、科学学院、应用科学学院、机械工程学院和医学学院）、不列颠哥伦比亚省圣保罗鼻窦中心（心肺创新中心）和澳大利亚伍尔科克医学研究所（悉尼大学）的专家团队与设备制造商Enwave Inc.合作，BC提出开发一种可呼吸的诱饵：使用与病毒受体结合的胶囊化重组血管紧张素转换酶2（rhACE 2）的可吸入微粒。这些微粒将被设计成通过吸入器释放到早期症状患者的呼吸道内，在病毒到达目标之前与病毒表面结合。我们的解决方案并不旨在成为Covid-19的疫苗，而是旨在利用病毒受体亲和力来创造治疗SARS-CoV-2感染症状的解决方案。